These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25268808)

  • 1. Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies.
    Zhao R; Huang Y; Cheng G; Liu J; Shao P; Qin C; Hua L; Yin C
    PLoS One; 2014; 9(9):e106933. PubMed ID: 25268808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing a model for forecasting Gleason score ≥7 in potential prostate cancer patients to reduce unnecessary prostate biopsies.
    Li X; Pan Y; Huang Y; Wang J; Zhang C; Wu J; Cheng G; Qin C; Hua L; Wang Z
    Int Urol Nephrol; 2016 Apr; 48(4):535-40. PubMed ID: 26810323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical usefulness of free PSA in early detection of prostate cancer.
    Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
    Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA.
    Zhao J; Liu S; Gao D; Ding S; Niu Z; Zhang H; Huang Z; Qiu J; Li Q; Li N; Xie F; Cui J; Lu J
    Oncotarget; 2017 Feb; 8(6):9935-9946. PubMed ID: 28039477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.
    Chiu PK; Roobol MJ; Teoh JY; Lee WM; Yip SY; Hou SM; Bangma CH; Ng CF
    Int Urol Nephrol; 2016 Oct; 48(10):1631-7. PubMed ID: 27349564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values.
    Yilmaz H; Ciftci S; Yavuz U; Ustuner M; Saribacak A; Dillioglugil O
    Kaohsiung J Med Sci; 2015 Jun; 31(6):315-9. PubMed ID: 26043411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
    Chen R; Huang Y; Cai X; Xie L; He D; Zhou L; Xu C; Gao X; Ren S; Wang F; Ma L; Wei Q; Yin C; Tian Y; Sun Z; Fu Q; Ding Q; Zheng J; Ye Z; Ye D; Xu D; Hou J; Xu K; Yuan J; Gao X; Liu C; Pan T; Sun Y;
    PLoS One; 2015; 10(6):e0130308. PubMed ID: 26091007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma.
    Bazinet M; Meshref AW; Trudel C; Aronson S; Péloquin F; Nachabe M; Bégin LR; Elhilali MM
    Urology; 1994 Jan; 43(1):44-51; discussion 51-2. PubMed ID: 7506853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
    Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
    Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients.
    Huang Y; Cheng G; Liu B; Shao P; Qin C; Li J; Hua L; Yin C
    BMC Urol; 2014 Jan; 14():8. PubMed ID: 24410803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
    Tarcan T; Ozveri H; Biren T; Türkeri L; Akdas A
    Int J Urol; 1997 Jul; 4(4):362-7. PubMed ID: 9256325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
    Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
    Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.
    Nan LB; Yin XT; Gao JP
    Med Sci Monit; 2019 Nov; 25():8345-8351. PubMed ID: 31691648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.